Dawa Pharmaceutical Invest Sweden AB
ABActiveOrg 5568460041C/O Kungspoprtsavenyn 4, 411 36 GöteborgOther financial service activities, except insurance and pension funding n.e.c.· NACE 6499Est. 2011 · 15 years old0 employees
Loading company…
Overview
Dawa Pharmaceutical Invest Sweden AB is a Swedish AB based in Göteborg, operating in the Other financial service activities, except insurance and pension funding n.e.c. sector. Incorporated in 2011, the company has 0 employees and reported revenue of SEK 0 in its latest annual filing.
Revenue 2024
0M SEK
EBITDA margin
—
Net profit 2024
0.1M SEK
+284% vs 2023
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
0.3 %
Very weakAmong the 10% lowest rated companies in the industry
20202024
Liquidity ratioCurrent assets ÷ Short-term debt
1.5×
WeakAmong the 40% lowest rated companies in the industry
20202024
Return on assets (ROA)Net profit ÷ Total assets × 100
0.2 %
AverageAround the average of companies in the same industry
20202024
EBITDA — year on year
SEK thousandsKey figures
Annual report 2024| Revenue | 0M SEK | — |
| EBITDA | -7.7M SEK | -2513% |
| Net profit | 0.1M SEK | +284% |
| Total assets | 51.2M SEK | +251% |
| Equity | 0.2M SEK | +196% |
| Employees | 0 | — |
Company information
Legal name
Dawa Pharmaceutical Invest Sweden AB
Org number
5568460041
Legal form
Aktiebolag
Founded
15 March 2011 · 15 years
Share capital
SEK 50,000
Employees
0 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva investeringar och handel med värdepapper i främst läkemedels- och medicinteknikbolag, både noterade och onoterade. Bolaget får även äga och förvalta aktier, andelar och andra finansiella instrument samt bedriva därmed förenlig verksamhet.
(no translation available)
Contact
Address
C/O Kungspoprtsavenyn 4, 411 36 Göteborg
Email
bo.rydlinger@sofama.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2024), Dawa Pharmaceutical Invest Sweden AB reported revenue of SEK 0. The figures on this page draw on 5 annual filings covering 2020 to 2024. The bottom line showed a net profit of SEK 105.8k.
At the end of 2024, equity financed 0.3% of the balance sheet, and current assets covered short-term debt 1.5 times.
Financials
Revenue
SEKEBITDA
SEK thousandsIncome statement
SEK thousands| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | — | — | — |
| EBITDA | -7,685 | 318 | -24 | -32 | -32 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -7,685 | 318 | -24 | -32 | -32 |
| Net financials | 7,790 | -137 | -118 | 51 | 232 |
| Profit before tax | 106 | -43 | 31 | 50 | 293 |
| Tax | -0 | -14 | -0 | -0 | -0 |
| Net profit | 106 | -57 | 31 | 50 | 293 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | 51,193 | 14,569 | 689 | 1,719 | 1,671 |
| Equity | 160 | 54 | 111 | 480 | 430 |
| Long-term debt | 17,989 | 821 | 542 | 1,209 | 1,211 |
| Short-term debt | 33,044 | 13,694 | 35 | 30 | 30 |
| Total debt | 51,033 | 14,515 | 577 | 1,239 | 1,241 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20202024
Equity ratio
0.3 %
Very weakAmong the 10% lowest rated companies in the industry
20202024
Return on equity
66.2 %
Very strongAmong the 20% highest rated companies in the industry
20202024
Net profit margin
>999 %
20202024
Asset turnover
0.00×
Very weakAmong the 10% lowest rated companies in the industry
20202024
Debt / equity
319.52×
Very weakAmong the 10% lowest rated companies in the industry
20202024
Sector performance
22 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very strong
Among the 20% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very strong
Among the 20% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 40% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 40% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 20% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery weak
Among the 10% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 10% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest rate on debtVery strong
Among the 10% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Interest coverageNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The ability to pay the interest on the company's debt out of its earnings.
Efficiency & development
Asset turnoverVery weak
Among the 10% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalWeak
Among the 30% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AG Chief Auditor | Chief Auditor | 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
EH Deputy Board Member | Deputy Board Member | 2022 |
BG Board of Directors | Board of Directors | 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Marstrandsgruppen AB
Dawa Pharmaceutical Invest Sweden AB Board network connections
Board members of Dawa Pharmaceutical Invest Sweden AB also hold positions in 313 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Gunnar Blohmé | Chief Auditor | 281 companiesMany roles |
| Bo Gunnar Rydlinger | Board of Directors | 22 companiesMany roles |
| Eva Helene Rydlinger | Deputy Board Member | 10 companiesMany roles |
Frequently asked questions
What is the Org number of Dawa Pharmaceutical Invest Sweden AB?
Dawa Pharmaceutical Invest Sweden AB is registered with Bolagsverket / SCB under Org 5568460041.
Where is Dawa Pharmaceutical Invest Sweden AB headquartered?
Dawa Pharmaceutical Invest Sweden AB's registered address is C/O Kungspoprtsavenyn 4.